Syncromune(R), Inc. Presents Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at Society of Urological Oncology 26th Annual Meeting
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) — Syncromune(R), Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ platform combination therapy optimized for solid tumor cancers, today announced the presentation of findings from its Phase 1 clinical study of SYNC-T Therapy SV-102 in patients […]